Call for patient identification: FGFR1-rearranged MLN patients
Myeloid/Lymphoid Neoplasms (MLN) with a rearrangement of the FGFR1 gene is a rare but extremely aggressive malignancy.
Within the CMWP, a study has been proposed to determine the overall survival, relapse incidence and non-relapse mortality rates after transplantation of these FGFR1-rearranged MLN patients.
Due to the rarity of the condition, it is very valuable to identify and receive information about every single patient within the reach of EBMT. Currently, we have identified 16 eligible patients in the registry and are hoping to enlarge this number.
- Diagnosis of FGFR1rearranged MLN (based on 8p11 rearrangement on cytogenetics);
- Age ≥ 18 years;
- Any type of transplant (first or subsequent transplant / any source of the hematopoietic stem cells / any type of conditioning regimen / any degree of HLA compatibility).
If you are interested in this study, please contact Nienke Zinger (firstname.lastname@example.org).
Call for participation: MF Ruxolitinib
We would like to invite you to participate in a retrospective study of the Chronic Malignancies Working Party regarding the effect of pretreatment with JAK inhibitor ruxolitinib in patients with primary or post ET/PV myelofibrosis on outcome after allogeneic HSCT.
For this study we seek to include MF patients with and without such prior treatment.
In this retrospective EBMT registry study the impact of ruxolitinib treatment prior to allogeneic HSCT on outcome such as engraftment, graft–versus-host disease, non-relapse mortality, relapse and overall survival will be addressed and compared to patients who received - in the same time period - allogeneic HSCT without ruxolitinib pretreatment.
- patients with primary or post ET/PV myelofibrosis
- allogeneic HSCT between 01-01-2012 and 31-12-2016
- age 18 – 75
- informed consent
- no information about ruxolitinib treatment or other pretreatment.
- blastic phase of myelofibrosis (transformation to AML before allogeneic HSCT).
The proposal is available upon request.
If you are interested in this study, please contact Tiarlan Sirait (email@example.com)
Call for participation: Missing primary cancer data request
Patients with therapy-related myeloid neoplasms (t-MNs) account for about 10 to 20% of all cases of AML and MDS. Given the increasing number of long-term cancer survivors, more patients are expected to be diagnosed with t-MN in the near future.
Within the CMWP, a study has been proposed to update the transplant outcomes of t-MN patients, assess the rate of long-term complications and identify the pre-HSCT and HSCT-related risk factors.
Yet, although we do know that we have many potential eligible patients for this study in our database, the type of primary cancer is often missing. Therefore, we are looking for centers who are willing to participate in our data request by providing the type of primary cancer and its diagnosis date.
- Adults (at time of transplant).
- Diagnosis of tMN (t-AML and t-MDS), in ProMISe: secondary AML or secondary MDS.
- First allogeneic transplant between January 2006 and December 2016.
- Prior history of solid cancer or haematological malignancy, treated by radiotherapy, chemotherapy, or both (including autologous transplant).
If you are interested in this study, please contact Nienke Zinger (firstname.lastname@example.org)
Call for participation: Myeloproliferative Neoplasms Unclassified (MPN-U)
We would like to invite you to participate in a retrospective study of the Chronic Malignancies Working Party regarding the Outcome of Allogeneic Haematopoietic Stem Cell Transplantation in Myeloproliferative Neoplasms – Unclassified (MPN-U).
In this retrospective EBMT registry study the impact of the condition regimen intensity on the outcome of AHSCT for MPN-U will be addressed.
- Patients with MPN-U diagnosis
- First Allo SCT: RIC and Myeloablative including Cord and Haplo
- Allogeneic HSCT between 01-01-2000 and 31-12-2015
- Age ≥ 18
- Stem cell source: BM and PB
- Donor: Sibling and URD HLA-identical and HLA-mm
The proposal is available upon request.
If you are interested in this study, please contact Esther Hazelhoff (email@example.com)